



## Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 19, 2023

BRISBANE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) ("Day One" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 42<sup>nd</sup> Annual J.P. Morgan Healthcare Conference on Monday, January 8 at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time.

A live audio webcast of the presentation will be available by visiting the Events & Presentations section of the Company's website at [www.dayonebio.com](http://www.dayonebio.com). An archived replay of the webcast will be available for 30 days following the live presentation.

### About Day One Biopharmaceuticals

Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company that believes when it comes to pediatric cancer, we can do better. We put kids first and are developing targeted therapies that deliver to their needs. Day One was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. The Company's name was inspired by "The Day One Talk" that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. Day One aims to re-envision cancer drug development and redefine what's possible for all people living with cancer—regardless of age—starting from Day One.

Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company's lead product candidate, tovorafenib, is an investigational, oral, brain-penetrant, highly-selective type II RAF kinase inhibitor currently under U.S. Food and Drug Administration priority review in BRAF-altered relapsed or progressive pediatric low-grade glioma. The Company's pipeline also includes pimasertib, an investigational, oral, highly-selective small molecule inhibitor of mitogen-activated protein kinases 1 and 2 (MEK-1/-2). Day One is based in Brisbane, California. For more information, please visit [www.dayonebio.com](http://www.dayonebio.com) or find the Company on LinkedIn or X, formerly known as Twitter.

### DAY ONE MEDIA

Laura Cooper, Head of Communications  
[media@dayonebio.com](mailto:media@dayonebio.com)

### DAY ONE INVESTORS

LifeSci Advisors, PJ Kelleher  
[pkelleher@lifesciadvisors.com](mailto:pkelleher@lifesciadvisors.com)